Prelude Therapeutics (PRLD) Free Cash Flow (2019 - 2026)

Prelude Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$21.7 million in Q1 2026.

• Quarterly Free Cash Flow rose 36.74% year-over-year to -$21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.8 million (up 58.35% YoY) and the FY2025 annual result came in at -$56.4 million, up 45.22% from the prior year.
• Free Cash Flow eased to -$21.7 million in Q1 2026 per PRLD's latest filing, from $23.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $23.1 million in Q4 2025 and troughed at -$34.3 million in Q1 2025.
• A 5-year average of -$22.1 million and a median of -$23.4 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow tumbled 44.53% in 2023, then surged 215.35% in 2025.
• Over 5 years, Free Cash Flow stood at -$22.7 million in 2022, then declined by 8.87% to -$24.7 million in 2023, then advanced by 18.88% to -$20.0 million in 2024, then soared by 215.35% to $23.1 million in 2025, then sank by 193.8% to -$21.7 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$21.7 million, $23.1 million, and -$19.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.